Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dysbindin domain-containing protein 2 (DBNDD2)
- Target
- DBNDD2
- Molecular classification
- Other (no evidence for inclusion in major therapeutic protein families like receptor, enzyme, transcription factor, transporter, or ion channel), Predicted ATPase binding protein, Casein kinase-1 binding protein
01
Overview
Dysbindin domain-containing protein 2 (DBNDD2) is a cytoplasmic protein encoded by the DBNDD2 gene, located on human chromosome 20. It is predicted to enable ATPase binding activity and participate in the negative regulation of protein kinase activity. DBNDD2 is found in the cytoplasm, endoplasmic reticulum, and lysosome, but its precise molecular function remains unclear. Transcriptomic studies suggest a role in cellular adaptation to neuronal injury and stable baseline expression across varied tissues. The protein is sometimes referred to as Casein kinase-1 binding protein due to its known interaction. Currently, DBNDD2 is primarily of interest in basic research and as a reference gene in quantitative expression studies, rather than as a direct therapeutic target.
- Other names
- C20orf35CK1BPHSMNP1Dysbindin (dystrobrevin binding protein 1) domain containing 2
02
Mechanism of action
None applicable, as there are no drugs or well-characterized modulators for this protein
03
Biological functions
Negative regulation of protein kinase activityPredicted ATPase binding activityPredicted activity in cytoplasm, endoplasmic reticulum, and lysosomePossibly involved in neurometabolic adaptation and neuronal injury responseStable expression as reference gene in tissue expression studies
04
Disease associations
Implicated in cellular response to chronic neuronal injury (e.g., after stroke), but no direct disease association or primary disease role establishedHousekeeping reference gene role in tissue studiesNo direct links to cancer, inflammation, neurodegenerative, or other major diseases established in public sources
Beyond the preview
Go deeper on Dysbindin domain-containing protein 2 (DBNDD2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dysbindin domain-containing protein 2 (DBNDD2).